Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL8177 in active ulcerative colitis
NCT05466890Phase 2Active, not recruiting
- Sponsor
- Palatin Technologies, Inc.
- Start
- Sep 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of PL8177 in ulcerative colitis (UC), sponsored by Palatin Technologies, Inc.. Started Sep 2022; status: active, not recruiting.
02
Drugs
PL8177
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05466890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466890.